gms | German Medical Science

65th Annual Meeting of the German Association for Medical Informatics, Biometry and Epidemiology (GMDS), Meeting of the Central European Network (CEN: German Region, Austro-Swiss Region and Polish Region) of the International Biometric Society (IBS)

06.09. - 09.09.2020, Berlin (online conference)

Artikel

Artikel empfehlen

Model-based dose-finding for combination studies

Meeting Abstract

Suche in Medline nach

  • Thomas Jaki - Lancaster University, Lancaster, United Kingdom
  • Pavel Mozgunov - Lancaster University, Lancaster, United Kingdom
  • Marianna Grinberg - Merck Healthcare KGaA, Darmstadt, Germany

Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie. 65th Annual Meeting of the German Association for Medical Informatics, Biometry and Epidemiology (GMDS), Meeting of the Central European Network (CEN: German Region, Austro-Swiss Region and Polish Region) of the International Biometric Society (IBS). Berlin, 06.-09.09.2020. Düsseldorf: German Medical Science GMS Publishing House; 2021. DocAbstr. 10

doi: 10.3205/20gmds021, urn:nbn:de:0183-20gmds0212

Veröffentlicht: 26. Februar 2021

© 2021 Jaki et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.

Gliederung

Text

Increasingly, Phase I cancer trials consider combinations of agents. Typically, such a study would allow escalation of one agent at a time, provided the lower combination has been shown to be safe, with the goal of these studies usually being to find the maximum tolerated combination (MTC). In recent years a large range of different model-based and model-assisted approaches have been proposed, each claiming to be (at least in some instances) being better than the others.

In this presentation we will discuss several different model-based approaches for combination dose-finding studies and compare them in a comprehensive simulation study. We incorporate practical constraints in such studies when one of the agents is already in use (and hence has an established dose-level). We show that allowing the escalation methods to escalate freely without restricting to the dose of the established agent yields superior performance for all methods and find that, while all methods perform adequate, small improvements by using a model incorporating interactions can be achieved.

The authors declare that they have no competing interests.

The authors declare that an ethics committee vote is not required.